NCT07658833Recruiting
TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
Study of the Safety, Clinical Efficacy and Prognostic Factors of TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 22 Jun 2026
Brief summary (registry, in English)
The safety, clinical efficacy and prognostic factors of transcatheter arterial chemoembolization (TACE) and/or hepatic artery infusion chemotherapy (HAIC) combined with targeted immunotherapy for primary hepatocellular carcinoma (HCC) require further in-depth study. This research aims to evaluate the safety, clinical efficacy and prognostic factors of TACE and/or HAIC combined with targeted immunotherapy for hepatocellular carcinoma. We are going to compare and analyze local tumor response, survival outcomes, prognostic factors and adverse events. Tumor response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) version. Adverse events were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. This study intends to include the targeted and immunotherapy applied, mainly including: lenvatinib, sorafenib, apatinib, bevacizumab, etc.; pembrolizumab, carfilzomib, sintilimab and teprotumumab, etc.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 29 May 2026
- Start date
- 1 Jul 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07658833
What you commit to
- Study type: Observational
- Planned participants: 120
- From 1 Jul 2026 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- prior anti-tumor therapy
Other illness
- with other malignancies
- history of drug allergy
- autoimmune diseases
- digestive hemorrhage of any grade
Other
- insufficient renal, bone marrow, or coagulation function
Who the study is looking for
- aged 18-80 years
- Eastern Cooperative Oncology Group (ECOG) performance status score \< 2
- maximum tumor diameter ≥ 7 cm
- IVC/RA TT diagnosed by contrast-enhanced CT / MRI before study treatment
- unresectable HCC (uHCC) confirmed by a specialized multidisciplinary team
- liver function of Child-Pugh class A or B
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Jiayan Ni Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.